EU Labeling Contraindicates Acomplia for Patients with Depression
Acomplia (generic name Rimonabant) was not approved in the US because the FDA’s expert panel was concerned about suicidal thoughts that appeared as a treatment side-effect in patients. Acomplia is a drug that was approved in the EU for treatment of weight loss and diabetes. According to Forbes, the European Medicines Agency (EMEA) has updated the drug’s labeling to contraindicate (NOT USE due to dangerous including potentially fatal side effects) the use of this drug for patients who have major depression and/or are receiving ongoing antidepressive treatment. You may also read the company’s PDF press release here.
Comments
Leave a Reply